Semax

What it is

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) representing a fragment of adrenocorticotropic hormone (ACTH 4-7) with a tripeptide extension added for stability. It is approved as a pharmaceutical in Russia (Семакс) for ischemic stroke, cognitive disorders, and certain ADHD-spectrum presentations in children. Like Selank, it has not been approved in the United States or Western Europe, and Semax is not FDA-approved for any use in the United States.

Semax was developed beginning in the 1970s by the Institute of Molecular Genetics of the Russian Academy of Sciences as a modified ACTH fragment. Semax has been used in Russia for decades, and most of its published research appears in Russian-language journals.

Mechanism of action

Proposed mechanisms come from laboratory and animal research:

• BDNF and neurotrophic effects: in animal studies, Semax has been reported to increase brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical regions.
• Dopaminergic modulation: animal studies have reported changes in dopamine signaling in brain circuits associated with attention.
• Cholinergic effects: effects on acetylcholine signaling have been reported in animal models.
• Anti-ischemic effects: in animal models of cerebral ischemia, Semax has been reported to reduce markers of neuronal injury.

Research findings

Studies conducted mainly in Russia have reported the following; these findings have not been evaluated by the FDA:

Acute ischemic stroke: Russian trials of Semax in the acute and subacute phases of stroke have been published; benefit in people has not been established.

Cognitive disorders: Russian studies in cerebrovascular cognitive impairment and post-stroke cognitive decline have been published; benefit in people has not been established.

Attention disorders: Semax has been studied in pediatric ADHD-spectrum presentations in Russia; benefit in people has not been established, and these findings have not been replicated in Western settings.

Healthy adults: small studies in healthy adults have examined attention and cognitive performance under conditions including cognitive load and sleep deprivation.

Western replication is limited, and well-controlled human trials establishing the effectiveness and safety of Semax under US standards are lacking.

Side effects and contraindications

The safety of Semax has not been established in well-controlled trials meeting US regulatory standards, and long-term safety outside Russian research has not been formally characterized. Products sold outside regulated channels (for example, as “research peptides”) may vary in purity, dose, and sterility.

Concerns have been raised for: pregnancy and breastfeeding, severe psychiatric conditions, known peptide allergies, and seizure disorders (theoretical caution given reported CNS effects).

What we don’t yet know

Western RCT replication of Russian clinical findings is lacking. Long-term safety with repeated use is not well characterized in formal studies. Comparative effectiveness vs. conventional treatments and behavioral interventions has not been established in head-to-head studies. Whether Semax has any meaningful cognitive effect in healthy adults (vs. only in disease states) is debated and probably overstated in marketing claims.